Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration

Executive Summary

Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments

You may also be interested in...



Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron? 

Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26

Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron? 

Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26

Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says

Treatment with Roche's Pegasys/Copegus should be dosed according to hepatitis C virus genotype in order to optimize the product's risk/benefit ratio, FDA's Antiviral Drugs Advisory Committee recommended

Related Content

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel